Piramal Pharma Appoints Viral Gandhi as Chief Technology Officer
Piramal Pharma Limited has appointed Mr. Viral Gandhi as Chief Technology Officer and Senior Management Personnel, effective October 1, 2026. Mr. Gandhi brings over two and a half decades of experience in technology and digital strategy, having previously served as Group CIO for Piramal Group.
The appointment of a Chief Technology Officer can significantly influence a company's future technological direction, innovation, and operational efficiency. While not immediately impacting financials, it has strategic importance.
The appointment of a new CTO is a routine management change and does not inherently indicate a positive or negative shift for the company's financial performance or market position.
Piramal Pharma Limited (PPL) announced the appointment of Mr. Viral Gandhi as its Chief Technology Officer (CTO) and a Senior Management Personnel. The decision was approved by the Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, and is effective from 1st October, 2026.
Mr. Gandhi's profile highlights his extensive experience as President and Group Chief Information Officer for the Piramal Group, where he has been instrumental in driving technological innovation and digital transformation. His prior roles include Chief Information Officer at Cox & Kings Group and significant contributions to technology transformation initiatives for Fortune 100 clients during his tenure at Tata Consultancy Services (TCS).
He holds an Executive Leadership Program from Harvard Business School and a Strategy and Innovation Program from MIT, with a Bachelor's Degree in Engineering from VJTI, Mumbai. Mr. Gandhi is not related to any Director of the Company. The company has also made this information available on its website.
What to do with a filing like this
Piramal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Piramal Pharma Limited. Read the original for the full detail.